News & Analysis

Curated news and analysis on clinical trials, drug approvals, and medical research.

Innovative Funding and Digital Twins Drive Rare Disease Drug Development

New investment models and digital twin technologies are bridging gaps in rare disease drug development, where traditional funding and trial designs fall short. Patient-led funding and family offices provide capital, while regulators accept digital evidence to accelerate therapies for the more than 7,000 rare diseases with few approved treatments.

Newer
Sorted by date
Older
Showing 20 articles per page